Abstract
Recognising that mild asthmatics are at risk of exacerbations and mortality, the Global Initiative for Asthma (GINA) issued an updated strategy in 2019. This was premised on two studies culminating in their recommendation that mild asthma should be treated by using a combination of a rapid and long-acting beta 2 agonist and an inhaled corticosteroid (ICS) administered as required. Their rationale is, however, debatable, as the studies actually showed that regular daily ICS administration was more effective for a number of asthma control endpoints. A patient-driven treatment strategy is also questionable, as there are a number of concerns about behaviour of patients suffering from asthma and perception of airway narrowing that should trigger medication intake but in fact does not do so. These deficiencies also influence a similar maintenance and reliever treatment (MART) approach that would be suboptimal. Intermittent ICS regimens are also inferior when compared to regular treatment. Not all asthmatics respond to the same dose of ICS. The best way to manage asthma is by adopting a step-up ICS approach, to encompass varying disease severity, with a long-acting beta agonist taken on a daily basis, ideally in a single combination i...Continue Reading
References
Apr 1, 1983·British Journal of Clinical Pharmacology·R Ellul-Micallef, S A Johansson
Jul 1, 1995·Pediatric Pulmonology·A J MartinP M Yellowlees
Apr 1, 1997·Chest·A ChettaD Olivieri
Jun 3, 1999·American Journal of Respiratory and Critical Care Medicine·K C DoerschugJ N Kline
Jan 12, 2001·The European Respiratory Journal·K F RabeW C Maier
May 15, 2002·Chest·Ian MitchellPatrick A Hessel
Jan 10, 2004·The Journal of Allergy and Clinical Immunology·Robert A NathanTrudy B Pendergraft
Jul 17, 2004·American Journal of Respiratory and Critical Care Medicine·Eric D BatemanUNKNOWN GOAL Investigators Group
Apr 15, 2005·The New England Journal of Medicine·Homer A BousheyUNKNOWN National Heart, Lung, and Blood Institute's Asthma Clinical Research Network
Apr 11, 2006·British Journal of Pharmacology·Peter J Barnes
Jun 15, 2006·BMC Pulmonary Medicine·Martyn R PartridgeWilliam W Busse
Aug 29, 2006·Lancet·Klaus F RabeUmesh G Lalloo
Jul 20, 2007·Archives of Disease in Childhood·M TurpeinenT Haahtela
Jul 26, 2007·Respiratory Research·Anagnostis Valotis, Petra Högger
Jun 29, 2010·Thorax·Kenneth R ChapmanS Pedersen
Jun 13, 2014·NPJ Primary Care Respiratory Medicine·David PriceThys van der Molen
Jul 17, 2014·The Lancet. Respiratory Medicine·Sanjay Tanday
Mar 27, 2015·British Journal of Clinical Pharmacology·Peter T Daley-Yates
Apr 10, 2017·Advances in Therapy·Bo Ding, Mark Small
Apr 30, 2017·BMC Pulmonary Medicine·Robert Y SurukiFrank C Albers
Sep 11, 2017·The European Respiratory Journal·Paul M O'ByrneEric D Bateman
May 17, 2018·The New England Journal of Medicine·Eric D BatemanJ Mark FitzGerald
May 17, 2018·The New England Journal of Medicine·Paul M O'ByrneHelen K Reddel
Citations
Apr 30, 2020·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Corrado PelaiaNunzio Crimi
Jun 10, 2020·Allergy·Davinder KaurChristopher E Brightling
Oct 1, 2020·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·Trine H KaasBo L Chawes